Biolase Inc
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosme… Read more
Biolase Inc (BIOLQ) - Total Assets
Latest total assets as of September 2024: $27.24 Million USD
Based on the latest financial reports, Biolase Inc (BIOLQ) holds total assets worth $27.24 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biolase Inc - Total Assets Trend (2020–2023)
This chart illustrates how Biolase Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biolase Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Biolase Inc's total assets of $27.24 Million consist of 70.8% current assets and 29.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.7% |
| Accounts Receivable | $5.48 Million | 15.6% |
| Inventory | $11.43 Million | 32.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $2.93 Million | 8.3% |
Asset Composition Trend (2020–2023)
This chart illustrates how Biolase Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biolase Inc's current assets represent 70.8% of total assets in 2023, a decrease from 85.6% in 2020.
- Cash Position: Cash and equivalents constituted 18.7% of total assets in 2023, down from 42.8% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 7.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 32.6% of total assets.
Biolase Inc Competitors by Total Assets
Key competitors of Biolase Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Biolase Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Biolase Inc generates 1.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Biolase Inc is currently not profitable relative to its asset base.
Biolase Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.63 | 1.40 | 1.53 |
| Quick Ratio | 0.31 | 0.71 | 0.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-11.43 Million | $ 8.00 Million | $ 9.76 Million |
Biolase Inc - Advanced Valuation Insights
This section examines the relationship between Biolase Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -8.1% |
| Total Assets | $35.10 Million |
| Market Capitalization | $88.72 USD |
Valuation Analysis
Below Book Valuation: The market values Biolase Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biolase Inc's assets decreased by 8.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biolase Inc (2020–2023)
The table below shows the annual total assets of Biolase Inc from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $35.10 Million | -8.08% |
| 2022-12-31 | $38.19 Million | -30.93% |
| 2021-12-31 | $55.28 Million | +34.76% |
| 2020-12-31 | $41.02 Million | -- |